Germline mutation incidence in unselected PCa patient cohorts has been shown to range from 0.3 to 2.3% for BRCA1 and from 0.7 to 6% for BRCA2 [53,55,56,57,58,59,60]. This evidence concerns the gene BRCA2 and posterior cortical atrophy.